Liver Failure Dramatically Alters Opioid Peptide Levels in the Brain and Blood
Fulminant liver failure in rats causes significant changes in opioid peptide levels across multiple brain regions and plasma, supporting the use of opioid antagonists to treat hepatic encephalopathy.
Quick Facts
What This Study Found
Fulminant hepatic failure significantly altered Met-enkephalin, Leu-enkephalin, dynorphin A, and beta-endorphin levels in multiple brain regions and plasma.
Key Numbers
How They Did This
Rats were given thioacetamide to induce fulminant hepatic failure. Opioid peptide levels were measured in discrete brain regions and plasma using radioimmunoassay and compared to healthy controls.
Why This Research Matters
This study provided direct evidence that liver failure disrupts the brain's opioid peptide system, helping explain the neurological symptoms of hepatic encephalopathy and justifying opioid antagonist treatment.
The Bigger Picture
Understanding how liver failure affects brain opioid peptides has clinical implications for treating the millions of patients worldwide who develop hepatic encephalopathy from cirrhosis or acute liver failure.
What This Study Doesn't Tell Us
Animal study using chemically induced liver failure, which may not perfectly replicate human hepatic encephalopathy. The causal relationship between altered opioid levels and neurological symptoms was not directly established.
Questions This Raises
- ?Could monitoring opioid peptide levels help predict or stage hepatic encephalopathy?
- ?Which specific opioid receptor subtypes should be targeted for optimal treatment of hepatic encephalopathy?
Trust & Context
- Key Stat:
- 4 peptides altered across brain regions Met-enkephalin, Leu-enkephalin, dynorphin A, and beta-endorphin all showed significant changes in liver failure
- Evidence Grade:
- Moderate animal evidence with systematic measurement across brain regions. Provides mechanistic support for clinical use of opioid antagonists in hepatic encephalopathy.
- Study Age:
- Published in 1995, this study contributed to the evidence base for using naloxone and similar drugs in hepatic encephalopathy treatment.
- Original Title:
- Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 273(1), 185-92 (1995)
- Authors:
- Yurdaydin, C, Li, Y, Ha, J H, Jones, E A, Rothman, R, Basile, A S
- Database ID:
- RPEP-00349
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is hepatic encephalopathy?
Hepatic encephalopathy is a decline in brain function caused by severe liver disease. When the liver fails, toxins accumulate in the blood and affect the brain, causing confusion, personality changes, motor problems, and in severe cases, coma.
Why would opioid blockers help liver disease patients?
This study shows liver failure disrupts the brain's opioid peptide levels. The excess opioid signaling may contribute to the neurological symptoms. Blocking opioid receptors with drugs like naloxone can potentially reverse some of these symptoms.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00349APA
Yurdaydin, C; Li, Y; Ha, J H; Jones, E A; Rothman, R; Basile, A S. (1995). Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists.. The Journal of pharmacology and experimental therapeutics, 273(1), 185-92.
MLA
Yurdaydin, C, et al. "Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists.." The Journal of pharmacology and experimental therapeutics, 1995.
RethinkPeptides
RethinkPeptides Research Database. "Brain and plasma levels of opioid peptides are altered in ra..." RPEP-00349. Retrieved from https://rethinkpeptides.com/research/yurdaydin-1995-brain-and-plasma-levels
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.